Cure My Disease

Don't miss your cure!

 Log in / Sign up

New meningitis vaccine shows promise in teen trial

NCT ID NCT04490018

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new meningitis vaccine (MenQuadfi) in 463 healthy adolescents aged 10 to 17. It compared the new vaccine to an existing one (Nimenrix) and also checked if it could be given at the same time as HPV and Tdap-IPV vaccines. The goal was to see if the new vaccine provides similar protection against four types of meningococcal bacteria.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Meningococcal vaccine (MenQuadfi)
What this could lead to
If successful, this could provide a safe and effective option for protecting adolescents against four types of meningococcal disease, possibly with fewer shots.
What could go wrong
This is a completed phase 3 trial, so results are already in. However, the vaccine may not be superior to existing options, and rare side effects can only be fully assessed after wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS MENINGOCOCCAL IMMUNISATION

Contacts and locations

Locations

  • Investigational Site Number :3480001

    Győr, 9024, Hungary

  • Investigational Site Number :3480002

    Miskolc, 3527, Hungary

  • Investigational Site Number :3480003

    Budapest, 1042, Hungary

  • Investigational Site Number :3480004

    Szigetvár, 7900, Hungary

  • Investigational Site Number :3480006

    Szombathely, 7900, Hungary

  • Investigational Site Number :3800001

    Genova, IT-16132, Italy

  • Investigational Site Number :3800002

    Milan, Lombardy, 20154, Italy

  • Investigational Site Number :3800004

    Palermo, Sicily, 90131, Italy

  • Investigational Site Number :3800005

    Foggia, Apulia, 71122, Italy

  • Investigational Site Number :3800006

    Catanzaro, Calabria, 88100, Italy

  • Investigational Site Number :7020002

    Singapore, 229899, Singapore

  • Investigational Site Number :7240001

    Seville, Andalusia, 41013, Spain

  • Investigational Site Number :7240002

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number :7240003

    Madrid, Madrid, Comunidad de, 28007, Spain

  • Investigational Site Number :7240004

    Valencia, Valenciana, Comunidad, 46020, Spain

  • Investigational Site Number :7240005

    Esplugues de Llobregat, Castille and León, 08950, Spain

  • Investigational Site Number :7240006

    Santiago de Compostela, Galicia [Galicia], 15706, Spain

  • Investigational Site Number :7240007

    Puçol, Valenciana, Comunidad, 46530, Spain

  • Investigational Site Number :7240008

    Valencia, Valenciana, Comunidad, 46011, Spain

  • Investigational Site Number :7240009

    Valencia, Valenciana, Comunidad, 46022, Spain

  • Investigational Site Number :7240010

    Valencia, Valenciana, Comunidad, 46022, Spain

  • Investigational Site Number :7240011

    Burriana, Valenciana, Comunidad, 12530, Spain

  • Investigational Site Number :7240012

    Valencia, Valenciana, Comunidad, 46024, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.